Alkem Laboratories Limited (NSEI: ALKEM)
Health Care · Pharmaceuticals · IN
Rs5,220.00
-1.02% today · -4.1% 1Y
Alkem Laboratories Limited (NSEI: ALKEM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.48B and employs 19,346 people.
Over the last twelve months the share price has lost 4.1%, trading between 5.05K and 5.93K.
Tweenvest scores Alkem Laboratories Limited across four factors: quality 85/100, value 56/100, growth 48/100, dividend 72/100. Its strongest factor is quality.
ALKEM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.48B
- Revenue (TTM)
- $1.60B
- P/E
- 28.93
- EPS
- 180.45
- Dividend yield
- 1.02%
- Beta (5Y)
- 0.29
- 52-week high
- Rs5,933.50
- 52-week low
- Rs5,051.00
- Avg volume (3M)
- —
- Shares outstanding
- 119.56M
- Employees
- 19,346
- Next earnings
- —
About Alkem Laboratories Limited
Alkem Laboratories Ltd. functions as a pharmaceutical enterprise, engaged in the research, manufacturing, and worldwide distribution of both medicinal and nutritional products. Its comprehensive offerings encompass a variety of branded and generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and nutraceuticals. These products target both immediate and chronic health issues across numerous therapeutic areas, including anti-infectives, skin conditions, cardiovascular health, respiratory ailments, digestive problems, central nervous system disorders, cancer, urology, and women's health. The company also provides essential vitamins, minerals, and nutritional supplements, in addition to pain relief medications, anti-diabetic treatments, and neurological remedies. Complementing its core pharmaceutical lines, Alkem offers consumer health items such as pregnancy detection kits and condoms. Founded in 1973, the company's headquarters are located in Mumbai, India.
- ISIN
- INE540L01014
- Founded
- 1973
- Listed since
- Dec 23, 2015
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Glenmark Pharmaceuticals LimitedNSEI: GLENMARK | $6.83B | Rs2,331.00 | -2.06% |
| ALK-Abelló A/SCPSE: ALK B | $6.74B | Dkr228.80 | +13.49% |
| Ono Pharmaceutical Co., Ltd.TSE: 4528 | $6.71B | ¥2,257.50 | -0.73% |
| H. Lundbeck A/SCPSE: HLUN B | $6.64B | Dkr46.18 | +2.44% |
| Belite Bio, IncNasdaqCM: BLTE | $6.43B | $156.08 | -2.18% |
| Ligand Pharmaceuticals IncorporatedNasdaqGM: LGND | $6.04B | $293.26 | -3.20% |
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.SZSE: 000999 | $6.00B | CN¥24.19 | +3.20% |
| Abbott India LimitedBSE: 500488 | $5.92B | Rs26,832.10 | -0.38% |
Figures last refreshed Oct 4, 2026.